DailyIQ
Last updatedjust now

PEN·Penumbra Inc.

$317.04
-0.07 (-0.02%)
After Hours
High
$318.00
Open
$317.10
Market Cap
12.52B
52W High
$373.00
Low
$316.87
P. Close
$317.04
P/E
77.97
52W Low
$221.26
Fwd P/E
51.71
DailyIQ Est.
$361.66
Inst. Ownership
1.3%
Short Interest
4.57%
Days to Cover
7.2
Technical Score (1D)
23
BEARISH
News Sentiment
58
BULLISH
On Oct 6, Penumbra, Inc. released results from a subset analysis of the STORM‑PE randomized controlled trial, showing a significant correlation between real‑world step activity captured on consumer wearables and performance on the 6‑minute walk test. The data, presented at the VIVA meeting, indicated that patients treated with computer‑assisted vacuum thrombectomy plus anticoagulation exhibited measurable functional recovery in daily life. These findings reinforced the clinical value of CAVT and may support broader adoption of wearable monitoring in pulmonary embolism management. The study demonstrated that wearable step data can serve as a reliable proxy for traditional functional assessments, providing a new avenue for evaluating patient outcomes outside the clinic. The results were highlighted as evidence that real‑world metrics can complement established clinical endpoints in the treatment of pulmonary embolism.
LOW TARGET
$323 +1.9%
3 analysts
MEAN TARGET
$362 +14.1%
14 analysts
HIGH TARGET
$374 +18.0%
5 analysts
PRICE RANGE
$323.00 - $374.00
SB / B / H / S / SS
1/5/14/1/1
DAILYIQ EST.
$361.66 (+14.1%)
Bought (1Y)
0 shares
$0
Sold (1Y)
1,230 shares
$392K
Narayan ShruthiPresident
Tax Withholding1,230 shares2026-09-15
Narayan ShruthiPresident
Award/Grant3,060 shares2026-08-17
84/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
67.1%
Net Margin
12.7%
Revenue CAGR
25.9%
Current Ratio
6.64x
Return on Equity
12.4%

EPS

EstBeatMiss
$0.88$0.97$1.05$1.14$1.22Q3'25Q3'26
QtrEstActual+/−
Q3'26$1.18 - -
Q3'25$0.92$0.97+5.3%

Revenue

EstBeatMiss
$347M$364M$381M$398M$415MQ3'25Q3'26
QtrEstActual+/−
Q3'26$407M - -
Q3'25 - $355M -

Market Data

PEN Stock Snapshot

BEARISH23/100
$317.05+$0.01 (0.0%)
Market cap
12.52B
P/E ratio
78.0
Day range
$316.87 – $318.00
News sentiment
58/100 · Neutral
Analyst target
$361.83 (+14.1%)
Consensus
Hold · 22 analysts
52-week range+43.3% off low · -15.0% from high
$221.26$373.00
Price $317.05 DailyIQ Est. $361.66

PEN is on the weaker side of its setup, with little confirmation for a reversal yet. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What PEN's own history says about today's numbers

Realized volatility (21d)
8.2% 3rd pct
Below its peak
-13.1%
vs 200-day average
-3.0%
Up days (1y)
50%

Penumbra Inc. is currently running 8.2% annualised volatility over the last 21 sessions. Measured against PEN's own 11 years of daily returns rather than a market-wide average, that is the 3rd percentile — unusually subdued by its own history, against a typical reading of 36.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

PEN is trading -13.1% below its running peak. Across 10 full years on file, its median worst-drawdown-in-a-year was -29.8%, and the deepest was -59.1% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -3.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 24th percentile — a narrower gap than it typically runs. Over the past year PEN closed higher on 50% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 11 years of records, PEN finished the month higher 5 of 11 times, with a median return of -7.4% and an average of +1.9%. Its strongest month historically has been November at +8.9% on average, its weakest May at -1.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: PEN has opened more than 2% away from the prior close in 135 of 2,776 sessions (4.9% of the time), with the largest gaps running +9.4% and -9.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 2,777 daily closes between 2015-09-18 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against PEN's own 11-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of PEN's sector?

Penumbra Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0

Options Market

What is the options market pricing for PEN?

CallsPuts

For Penumbra Inc.'s nearest expiry (2026-10-16, 10 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.45), with at-the-money implied volatility around 17.2%. The options market is pricing roughly a ±2.8% move by that expiry — a range of about $309.78–$327.94.

Put/call ratio (2026-10-16)
1.45
ATM implied volatility
17.2%
Total open interest
871
Expected move by 2026-10-16
±2.8% ($309.78–$327.94)

Analyst Rating Changes

Are analysts turning bullish or bearish on PEN?

Evercore ISI Group most recently reiterated its rating on Penumbra Inc. to Outperform on Jul 6, 2026 with a price target of $320 (from $335). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Evercore ISI Group — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Jul 6, 2026Evercore ISI GroupMaintainedOutperform$335 → $320
Jun 11, 2026RBC CapitalReiteratedSector Perform$374
May 7, 2026CitigroupMaintainedNeutral$374 → $350
May 7, 2026Evercore ISI GroupMaintainedOutperform$345 → $335
Feb 26, 2026Evercore ISI GroupMaintainedOutperform$340 → $360
Jan 20, 2026RBC CapitalDowngradeOutperform → Sector Perform$355 → $374
Jan 20, 2026Canaccord GenuityDowngradeBuy → Hold$359 → $374
Jan 16, 2026JefferiesDowngradeBuy → Hold$335 → $374
Jan 16, 2026NeedhamDowngradeBuy → Hold-
Jan 16, 2026CitigroupDowngradeBuy → Neutral$350 → $374
Jan 16, 2026Leerink PartnersDowngradeOutperform → Market Perform$374
Jan 16, 2026BairdDowngradeOutperform → Neutral$345 → $374

News Sentiment Analysis

Sentiment gathered from recent headlines

58/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

7 articles
What did this article say?
Penumbra, Inc. (NYSE: PEN) released results from a subset analysis of the STORM-PE randomized controlled trial, showing a significant correlation between real‑world step activity captured on consumer wearables and performance on the 6‑minute walk test. The data, presented at the VIVA meeting, suggest that patients treated with computer‑assisted vacuum thrombectomy plus anticoagulation exhibit measurable functional recovery in daily life. The findings reinforce the clinical value of CAVT and may support broader adoption of wearable monitoring in pulmonary embolism management.
What did this article say?
The article compares Penumbra (PEN) to Integra LifeSciences (IART) for value investors, noting that PEN holds a Zacks Rank of #3 (Hold) while IART has a #2 (Buy). PEN’s valuation metrics, such as P/E and P/S ratios, are evaluated but do not surpass IART’s stronger earnings outlook. The comparison suggests PEN is slightly less attractive for value-focused investors at present. No significant corporate actions or earnings surprises are highlighted for PEN. The piece serves as a relative valuation guide rather than a standalone investment thesis.
What did this article say?
The article compares Penumbra (PEN) with Integra LifeSciences (IART) for value investors. PEN holds a Zacks Rank of #3 (Hold) while IART is ranked #2 (Buy), indicating a more favorable earnings outlook for IART. Both companies are evaluated using Style Scores, but PEN’s valuation metrics appear less attractive. The piece suggests that PEN may be a less compelling value play at current levels. No material corporate action or earnings miss is reported.
What did this article say?
Penumbra (PEN) is evaluated as a hold by Zacks, with a #3 ranking, while Teleflex (TFX) receives a #2 buy. PEN’s valuation metrics—P/E, P/S, earnings yield, and cash flow per share—are less favorable than TFX’s, indicating a weaker value proposition. The article suggests PEN may need improved earnings revisions or better valuation multiples to become more appealing to value investors.
What did this article say?
The article compares Teleflex (TFX) and Penumbra (PEN) for value investors, noting both have strong Zacks Ranks (#2 for TFX, #3 for PEN). PEN’s valuation metrics—P/E, P/S, earnings yield, and cash flow per share—are highlighted as solid but not as improved as TFX’s recent earnings outlook. The piece suggests PEN remains a defensively positioned option for investors seeking undervalued medical‑instrument stocks, though it lacks the recent upside momentum seen in TFX.
What did this article say?
Penumbra (PEN) received FDA clearance for its THUNDERBOLT endovascular device following a robust stroke study, marking a significant regulatory milestone that could expand its market reach.
End of results

Technical Analysis

Real-time indicators across multiple timeframes

23
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $158.40M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold501,6631.27%$158.40M2026-09-02
Q2 2026 flow:501.7K sh bought ($158.40M)0 sh sold ($0)net +501.7K sh (+$158.40M)